Abstract
Chronic hepatitis B virus (HBV) infection remains a significant public health concern, particularly in Africa, where there is a substantial burden. HBV is an enveloped virus, with isolates being classified into ten phylogenetically distinct genotypes (A – J) determined based on full-genome sequence data or reverse hybridization-based diagnostic tests. In practice, limitations are noted in that diagnostic sequencing, generally using Sanger sequencing, tends to focus only on the S-gene, yielding little or no information on intra-patient HBV genetic diversity with very low-frequency variants and reverse hybridization detects only known genotype-specific mutations. To resolve these limitations, we developed an Oxford Nanopore Technology (ONT)-based HBV genotyping protocol suitable for clinical virology, yielding complete HBV genome sequences and extensive data on intra-patient HBV diversity. Specifically, the protocol involves tiling-based PCR amplification of HBV sequences, library preparation using the ONT Rapid Barcoding Kit, ONT GridION sequencing, genotyping using Genome Detective software, recombination analysis using jpHMM and RDP5 software, and drug resistance profiling using Geno2pheno software. We prove the utility of our protocol by efficiently generating and characterizing high-quality near full-length HBV genomes from 148 left-over diagnostic Hepatitis B patient samples obtained in the Western Cape province of South Africa, providing valuable insights into the genetic diversity and epidemiology of HBV in this region of the world.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.protocols.io/view/complete-hepatitis-b-virus-sequencing-using-an-ont-5qpvo3xxzv4o/v1
Funding Statement
This research was supported in part by the South African Medical Research Council (SAMRC) with funds received from the National Department of Health. Sequencing activities at KRISP and CERI are supported in part by grants from the Rockefeller Foundation (HTH 017), the Abbott Pandemic Defence Coalition (APDC), the National Institute of Health USA (U01 AI151698) for the United World Antivirus Research Network (UWARN) and the INFORM Africa project through IHVN (U54 TW012041), the SAMRC South African mRNA Vaccine Consortium (SAMVAC), the South African Department of Science and Innovation (SA DSI) and the SAMRC under the BRICS JAF #2020/049, European Union supported by the Global Health EDCTP3 Joint Undertaking and its members, European Unions Horizon Europe Research and Innovation Programme (101046041) and the Health Emergency Preparedness and Response Umbrella Program (HEPR Program), managed by the and the World Bank Group (TF0B8412). The content and findings reported herein are the sole deduction, view, and responsibility of the researcher/s and do not reflect the official position and sentiments of the funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Health Research Ethics Committee (HREC) approved the study at Stellenbosch University HREC: N22/08/089.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Abstract Revised to correct grammar. The introduction was revised to correct grammar and spelling. The discussion was revised to correct grammar and spelling.
Data Availability
All data produced within the manuscript are available on publically available databases.
